Overview

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Status:
Not yet recruiting
Trial end date:
2027-10-07
Target enrollment:
Participant gender:
Summary
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Tirzepatide